Boston, MA 10/07/2014 (wallstreetpr) – The week opened for PDL BioPharma Inc (NASDAQ:PDLI) with two new additions in its management team. Firstly, the company has appointed Danny Hat, who has already been working with the company since 2010, to the position of Vice President for business development. Secondly, the company added Nathan Kryszak to be a senior counsel.
Hart’s Role In The Company
PDL BioPharma Inc (NASDAQ:PDLI)’s President and CEO, John P. McLaughlin, illustrated the contribution of Mr. Hart towards evaluating transactions in relation to the company’s commitment of obtaining income generating assets. McLaughlin explained that Mr. Hat showed great aptitude in his work and thus, deems fit to be involved in the business aspect of the processes along with other external advisors.
McLaughlin is confident that the decision will help the company to achieve success in its program, which in turn could be shared with the shareholders through increased dividend payments. It is to be noted that Mr. Hart had been working in the capacity of deputy general counsel, corporate counsel and assistant secretary from January 2010 till now. In his early profile, Mr. Hart was responsible to manage in and out of the company’s investments.
Kryszak’s Background
At the same time, Nathan Kryszak, who was earlier working with White & Case LLP, an international law firm, has a tremendous hand on experience. He has expertise in both financial and legal aspects and thus, is considered apt for his new role in the company. In his earlier company, Kryszak served as a Senior Finance Associate. There he dealt with investment banking and private equity clients, helping them structure and manage series of financial transactions. Before his four years stint at White & Case LLP, Mr. Kryszak worked for six years at Cahill Gordon and Reindel, LLP. He is also a member at the Bars of the States of California and New York.
